Billy Rosson, MD
Pulmonary Disease · Lafayette, LANPI 1164414629
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 615 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by GSK at 29.9% of the total.
Across 615 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Sanofi$895
- Regeneron Healthcare Solutions, Inc.$808
- Boehringer Ingelheim$652
- Insmed, Inc.$461
- plus $3K from 31 others
What the payments were for
- Food & beverage$10,99799%
- Education$1471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 231 | $3,336 |
| AstraZeneca | 80 | $1,526 |
| Sanofi | 32 | $895 |
| Regeneron Healthcare Solutions, Inc. | 29 | $808 |
| Boehringer Ingelheim | 34 | $652 |
| Insmed, Inc. | 31 | $461 |
| Grifols USA, LLC | 22 | $441 |
| Mylan Specialty L.p. | 18 | $375 |
| Actelion Pharmaceuticals US, Inc. | 13 | $352 |
| Amgen | 11 | $203 |
| Mallinckrodt Hospital Products Inc. | 9 | $197 |
| Genentech USA, Inc. | 10 | $195 |
| Novartis | 11 | $193 |
| E.r. Squibb & Sons, L.L.C. | 11 | $162 |
| Merck | 7 | $156 |
| Bayer | 8 | $139 |
| United Therapeutics Corporation | 8 | $137 |
| Intuitive Surgical | 1 | $124 |
| Gilead | 8 | $120 |
| Electromed, Inc. | 8 | $71 |
| Verona Pharma, Inc. | 3 | $68 |
| Viatris Specialty LLC | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Johnson & Johnson | 4 | $56 |
| AbbVie | 3 | $46 |
| Astellas Pharma US Inc | 2 | $34 |
| Philips North America LLC | 2 | $32 |
| Circassia Inc. | 2 | $28 |
| Liquidia Technologies, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Acacia Pharma Inc | 1 | $20 |
| Pulmonx Corporation | 1 | $20 |
| UCB, Inc. | 1 | $20 |
| Livanova USA, Inc. | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $15 |
| EKOS Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,144 in reported general payments places this provider in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 190 | $150,663 |
| Fasenra PenBenralizumab | 14 | $78,338 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 112 | $52,832 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $27,002 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $21,035 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $12,094 |
| Spiriva HandihalerTiotropium Bromide | 22 | $11,194 |
| EliquisApixaban | 13 | $9,300 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $6,857 |
| Atrovent HfaIpratropium Bromide | 14 | $6,597 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 159 | $4,610 |
| Roflumilast | 44 | $4,526 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $4,159 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,616 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $3,336 | $242,591400 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,526 | $27,89243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Lafayette
- Frank CourmierLafayette$15K
- Timothy KeysLafayette$14K
- Walter BrownLafayette$12K
- George GuidryLafayette$9K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.